Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30

Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241

Richards KA, Smith ND, Steinberg GD (2014) The importance of transurethral resection of bladder tumor in the management of nonmuscle invasive bladder cancer: a systematic review of novel technologies. J Urol 191:1655–1664

National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Bladder Cancer. 2019 Version 1. http://www.nccn.org . Accessed 20 Dec 2018

Babjuk M, Böhle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447–461

Cumberbatch MG, Foerster B, Catto JW et al (2018) Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol 73:925–933

Naselli A, Hurle R, Paparella S et al (2017) Role of restaging transurethral resection for T1 non-muscle invasive bladder cancer: a systematic review and meta-analysis. Eur Urol Focus 4:558–567

Dobruch J, Borówka A, Herr HW (2014) Clinical value of transurethral second resection of bladder tumor: systematic review. Urology 84:881–885

Kim W, Song C, Park S et al (2012) Value of immediate second resection of the tumor bed to improve the effectiveness of transurethral resection of bladder tumor. J Endourol 26:1059–1064

Koie T, Ohyama C, Hosogoe S et al (2015) Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer. Int Urol Nephrol 47:1509–1514

Han KS, Joung JY, Cho KS et al (2008) Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 22:2699–2704

Schwaibold HE, Sivalingam S, May F et al (2006) The value of a second transurethral resection for T1 bladder cancer. BJU Int 97:1199–1201

Divrik T, Yildirim Ü, Şkin Eroğlu A et al (2006) Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer? J Urol 175:1258–1261

Divrik RT, Şahin AF, Yildirim Ü et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 58:185–190

Hashine K, Ide T, Nakashima T et al (2016) Results of second transurethral resection for high-grade T1 bladder cancer. Urol Ann 8:10–15

Sfakianos JP, Kim PH, Hakimi AA et al (2014) The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette–Guérin. J Urol 191:341–345

Herr HW, Dalbagni G, Donat SM (2011) Bacillus Calmette–Guérin without maintenance therapy for high-risk non-muscle-invasive bladder cancer. Eur Urol 60:32–36

Grossman HB, Stenzl A, Fradet Y et al (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188:58–62

Naito S, Algaba F, Babjuk M et al (2016) The Clinical Research Office of the Endourological Society (CROES) Multicentre Randomised Trial of Narrow Band Imaging-Assisted Transurethral Resection of Bladder Tumour (TURBT) versus conventional white light imaging-assisted TURBT in primary non-muscle-invasive bladder cancer patients: trial protocol and 1-year results. Eur Urol 70:506–515

Zhang J, Wang L, Mao S et al (2018) Transurethral en bloc resection with bipolar button electrode for non-muscleinvasive bladder cancer. Int Urol Nephrol 50:619–623

Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49:466–477

Fernandez-Gomez J, Madero R, Solsona E et al (2009) Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette–Guerin: the CUETO scoring model. J Urol 182:2195–2203

Li HM, Azhati B, Rexiati M et al (2017) Impact of smoking status and cumulative smoking exposure on tumor recurrence of non-muscle-invasive bladder cancer. Int Urol Nephrol 49:69–76

Xu T, Zhu Z, Wang X et al (2015) Impact of body mass on recurrence and progression in Chinese patients with Ta, T1 urothelial bladder cancer. Int Urol Nephrol 47:1135–1141

Mashni J, Godoy G, Haarer C et al (2014) Prospective evaluation of plasma kinetic bipolar resection of bladder cancer: comparison to monopolar resection and pathologic findings. Int Urol Nephrol 46:1699–1705

Teoh JY, Chan ES, Yip SY et al (2017) Comparison of detrusor muscle sampling rate in monopolar and bipolar transurethral resection of bladder tumor: a randomized trial. Ann Surg Oncol 24:1428–1434

Del Rosso A, Pace G, Masciovecchio S et al (2013) Plasmakinetic bipolar versus monopolar transurethral resection of non-muscle invasive bladder cancer: a single center randomized controlled trial. Int J Urol 20:399–403

Venkatramani V, Panda A, Manojkumar R et al (2014) Monopolar versus bipolar transurethral resection of bladder tumors: a single center, parallel arm, randomized, controlled trial. J Urol 191:1703–1707